$1.9M EBITDA MedTech Company - 2.3x EBITDA fixed entry multiple

profile

April 15, 2026

by a searcher from University of California, Los Angeles in Phoenix, AZ, USA

Fixed entry multiple is 2.3x EBITDA ($4.3m cash on closing with a $7.0m contingent payment). Preferred equity: 10% preferred return and 2.0x step up. Strong operating team of sponsors will take over management from the 70 year old husband and wife founders. Closing date: April 30th, 2026.
2
2
510
Replies
2
commentor profile
Reply by a searcher
from University of Redlands in Phoenix, AZ, USA
If you need a CEO to replace the founders I am definitely a strong fit and I am available. I've led 5 healthcare companies all aligned around the aging population. One company was a portable medical device company like this one. I am a GTM, sales and marketing expert, business transformation and restructuring expert, and have extensive experience leading organizations to transformational growth, organic and M&A rapid scaling, private equity, value creation and delivering strong exits. I currently live in Scottsdale but can easily and quickly relo back to LA where I led companies for 23 years, and where my adult children reside. Let's chat. Sean Kajcienski | CEO | Principal Consultant Private Equity Operator | Value Creation Leader | Fractional CEO COO CRO Pre-Acquisition Diligence | Post-Close Execution & Growth Acceleration Multi-Unit Platforms | Franchise | Healthcare | Franchise & Business Ownership Advisor Kaz Consulting Systems, LLC redacted Cell: (###-###-#### Calendar Link https://calendly.com/sean-kazconsultingsystems/30min ▸ I turn investment theses into results.
commentor profile
Reply by a lender
from Morehouse College in Birmingham, AL, USA
Hi Rania - I represent Stonehenge Capital and I'd love to chat about your debt capital need to complete this transaction. My e-mail address is redacted
Join the discussion